Q2 EBITDA exceeded guidance despite sales headwinds from challenging market conditions. Strategic actions, including asset sales and a major bond offering, are strengthening the balance sheet. Full-year guidance reflects lower sales and earnings, but restructuring and new product growth are expected to drive recovery in 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.